HIGH-DENSITY LIPOPROTEINS REDUCE THE INTESTINAL DAMAGE ASSOCIATED WITH ISCHEMIA/REPERFUSION AND COLITIS
Authors:
- Salvatore CuzzocreaSalvatore Cuzzocrea
- Laura DugoLDLaura Dugo
- Nimesh S. A PatelNPNimesh S. A Patel
- Rosanna Di PaolaRPRosanna Di Paola
- Gillian W CockerillGCGillian W Cockerill
- Tiziana GenoveseTGTiziana Genovese
- Christoph ThiemermannCTChristoph Thiemermann
- 1 April 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Shock
- Vol. 21 (4) , 342-351
Abstract
High-density lipoproteins (HDLs) have been shown to reduce the organ injury and mortality in animal models of shock by reducing the expression of adhesion molecules and proinflammatory enzymes. However, there is limited evidence that HDL treatment reduces inflammation. As inflammation plays an important role in the development of colitis as well as ischemia/reperfusion (I/R) injury of the intestine, we have investigated the effects of HDL in animal models of associated with gut injury and inflammation (splanchnic artery occlusion [SAO] shock and dinitrobenzene sulfonic acid [DNBS]-induced colitis). We report here for the first time that the administration of reconstituted HDLs (recHDLs; 80 mg/kg i.v. bolus 30 min prior to ischemia in the SAO-shock model or 40 mg/kg i.v. every 24 h in the colitis model) exerts potent anti-inflammatory effects (e.g., reduced inflammatory cell infiltration and histological injury, and delayed the development of the clinical signs) in vivo. Furthermore, recHDL reduced the staining for nitrotyrosine and poly(ADP-ribose) (immunohistochemistry) and the expression of intercellular adhesion molecule-1 in the ileum of SAO-shocked rats and in the colon from DNBS-treated rats. Thus, recHDL reduces the inflammation caused by intestinal I/R and colitis. HDLs may represent a novel therapeutic approach for the therapy of inflammation of the gut.Keywords
This publication has 45 references indexed in Scilit:
- High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shockThe FASEB Journal, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Role of poly(ADP-ribose) synthetase in inflammation and ischaemia–reperfusionTrends in Pharmacological Sciences, 1998
- What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo?FEBS Letters, 1997
- THE INTESTINAL CYTOKINE RESPONSE AFTER GOT ISCHEMIAShock, 1995
- Specificity of leukocyte-endothelial interactions and diapedesis: physiologic and therapeutic implications of an active decision processResearch in Immunology, 1993
- Oxygen radicals: mediators of gastrointestinal pathophysiology.Gut, 1989
- Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content.Gut, 1988
- Value of Indium-111 Granulocyte Scintigraphy in the Assessment of Crohn’s Disease of the Small Intestine: Prospective InvestigationDigestion, 1988
- Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemie myocardiumJournal of Pharmacological Methods, 1985